Cellectis (CLLS) Reports Q3 Loss of $0.36/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2016
November 22, 2016 5:01 PM EST- UCART19 Phase 1 trial on-going
- Successful cGMP Manufacturing for UCART123
- Strong cash position of $295 million1 as of September 30, 2016
- Additional grant of patent with broad claims covering fundamental use of gene editing technologies
- Revenues and other income of $12 million2 in the 3rd quarter of 2016
- Adjusted loss attributable to shareholders3 of $0.6 million2 in the 3rd quarter of 2016
NEW YORK--(BUSINESS WIRE)-- Regulatory News:
Cellectis S.A. (Paris: ALCLS) (NASDAQ: CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on... More
